EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieKohortenstudieOpen Access · CC BY-NC-ND 4.0

Outcomes of down syndrome-related myeloid leukemia in Turkiye: a multicenter retrospective observational cohort study by the Turkish Pediatric Hematology Association

Yeter Düzenli Kar, Hale Ören, Melike Sezgin Evim, Emine Zengin, Ekin Gün, Nihal Karadaş, Deniz Yılmaz Karapınar, Canan Albayrak, Selma Ünal, Feryal Karahan, Murat Söker, Veysiye Hulya Uzel und 14 weitere

Annals of Hematology · 2026

DOI: 10.1007/s00277-026-07245-0 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annals of Hematology, 2026. Verfasst von Yeter Düzenli Kar und 25 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Division of Pediatric Hematology, Department of Pediatrics, Bursa Uludag University, Bursa, Turkey. yeterduzenlikar@uludag.edu.t…. Hauptthemen laut MEDLINE: Down Syndrome, Leukemia, Myeloid, Acute, Leukemia, Myeloid. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Children with Down syndrome (DS) have a 150-times increased risk of myeloid leukemia (ML). In DS patients, in addition to DS-ML, common acute myeloid leukemia (AML) subtypes (standard-AML), observed in patients without DS, may also be seen. We evaluated ML types developing among DS cases, along with clinical features, survival, relapse, and mortality rates. The study included DS children aged 6 months to 18 years with newly diagnosed ML. Patients were classified retrospectively into two groups according to WHO guidelines and BFM-AML protocol recommendations as DS-ML and standard AML-DS. Among 53 DS patients, 71.7% (n = 38) had DS-ML and 28.3% (n = 15) had standard AML-DS. The mean age in the DS-ML group was significantly lower than the standard AML-DS group (23 ± 9 vs. 48 ± 51 months, p = 0.033). The 5-year overall survival (OS) and event-free survival (EFS) in the DS-ML group were 84.1%±6.0% and 81.3%±6.4%, respectively. For the standard AML, OS and EFS were 53.3%±12.9% and 45.7%±13.1%, respectively. The DS-ML group had significantly higher OS and EFS than the standard AML-DS group (p = 0.039 and p = 0.025, respectively). In our study, DS-ML and standard AML-DS were evaluated separately, which significantly contributes to the literature on the clinical and laboratory features of both groups, given the limited data on these topics. In the DS-ML group, complete remission, OS, and EFS were significantly higher than in the standard AML-DS. Differentiating DS-ML from standard AML-DS will ensure that patients with these biologically distinct diseases receive treatment of appropriate intensity and increase survival by reducing early mortality and relapse risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Down SyndromeLeukemia, Myeloid, AcuteLeukemia, MyeloidHumansChild, PreschoolRetrospective StudiesInfantChildFemaleTurkeyAdolescentMaleAntineoplastic Combined Chemotherapy ProtocolsDisease-Free SurvivalSurvival Rate

Stichwörter der Autor:innen

De novo acute myeloid leukemiaDown syndromeMyeloid leukemiaMyeloid neoplasia

Autor:innen und Institutionen

  • Faculty of Medicine, Division of Pediatric Hematology, Department of Pediatrics, Bursa Uludag University, Bursa, Turkey. yeterduzenlikar@uludag.edu.tr.
  • Faculty of Medicine, Division of Pediatric Hematology, Department of Pediatrics, Dokuz Eylül University, İzmir, Turkey.
  • Faculty of Medicine, Division of Pediatric Hematology, Department of Pediatrics, Bursa Uludag University, Bursa, Turkey.
  • Faculty of Medicine, Division of Pediatric Hematology, Department of Pediatrics, Kocaeli University, Kocaeli, Turkey.
  • Department of Pediatrics, Kocaeli University Faculty of Medicine, Kocaeli, Turkey.
  • Faculty of Medicine, Division of Pediatric Hematology, Department of Pediatrics, Ege University, Izmir, Turkey.

Zitieren

APA

Düzenli Kar, Y., Ören, H., Sezgin Evim, M., Zengin, E., Gün, E., Karadaş, N., Yılmaz Karapınar, D., Albayrak, C., Ünal, S., Karahan, F., Söker, M., Uzel, V. H., Akyay, A., Öncül, Y., Bahadır, A., Orhan, M. F., Çakı Kılıç, S., Tufan Taş, B., Güler Kazancı, E., …, & Meral Güneş, A. (2026). Outcomes of down syndrome-related myeloid leukemia in Turkiye: a multicenter retrospective observational cohort study by the Turkish Pediatric Hematology Association. Annals of Hematology. https://doi.org/10.1007/s00277-026-07245-0

Vancouver

Düzenli Kar Y, Ören H, Sezgin Evim M, Zengin E, Gün E, Karadaş N, et al. Outcomes of down syndrome-related myeloid leukemia in Turkiye: a multicenter retrospective observational cohort study by the Turkish Pediatric Hematology Association. Annals of Hematology. 2026. doi:10.1007/s00277-026-07245-0

BibTeX
@article{DzenliKar2026,
  author = {Düzenli Kar, Yeter and Ören, Hale and Sezgin Evim, Melike and Zengin, Emine and Gün, Ekin and Karadaş, Nihal and Yılmaz Karapınar, Deniz and Albayrak, Canan and Ünal, Selma and Karahan, Feryal and Söker, Murat and Uzel, Veysiye Hulya and Akyay, Arzu and Öncül, Yurday and Bahadır, Ayşenur and Orhan, Mehmet Fatih and Çakı Kılıç, Suar and Tufan Taş, Burcu and Güler Kazancı, Elif and Orhaner, Betül and Karapınar, Tuba Hilkay and Aral, Yusuf Ziya and Yaralı, Neşe and Fettah, Ali and Özkaya, Güven and Meral Güneş, Adalet},
  title = {Outcomes of down syndrome-related myeloid leukemia in Turkiye: a multicenter retrospective observational cohort study by the Turkish Pediatric Hematology Association},
  journal = {Annals of Hematology},
  year = {2026},
  doi = {10.1007/s00277-026-07245-0}
}
Kostenlos starten →